Impax Laboratories (NASDAQ:IPXL) : During the past 4 weeks, traders have been relatively bearish on Impax Laboratories (NASDAQ:IPXL), hence the stock is down -10.99% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.1% relative to the S&P 500. The stock has risen by 0.17% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.55% in the past 4 weeks.
The company shares have dropped -39.22% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $51.42 and the one year low was seen on May 10, 2016. The 50-Day Moving Average price is $31.56 and the 200 Day Moving Average price is recorded at $34.16.
The stock has recorded a 20-day Moving Average of 3.36% and the 50-Day Moving Average is 6.89%.
Impax Laboratories (NASDAQ:IPXL): stock turned positive on Friday. Though the stock opened at $29.3, the bulls momentum made the stock top out at $29.66 level for the day. The stock recorded a low of $29 and closed the trading day at $29.35, in the green by 0.79%. The total traded volume for the day was 751,239. The stock had closed at $29.12 in the previous days trading.
In an insider trading activity,The officer (President, Impax Pharm.) of Impax Laboratories Inc, Nestor Michael sold 5,000 shares at $43.56 on September 10, 2015. The Insider selling transaction had a total value worth of $217,800. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.